• Atención pediátrica
  • Atención del cáncer

Renown Children’s Hospital se une a Children’s Oncology Group

5 de enero de 2022

Dr. J. Martin Johnston, Renown Health's Chief of Hematology and Oncology with Patient

Dr. J. Martin Johnston, Renown Health's Chief of Hematology and Oncology.

Renown now home to northern Nevada's only Children's Oncology Group institution, giving local pediatric cancer patients access to the most cutting-edge treatments.

Renown Children's Hospital announced today that it is now a member of the Children's Oncology Group (COG), the world's largest organization devoted exclusively to childhood cancer. Membership in the COG allows Renown to enroll its youngest patients in the latest clinical trials, including ground-breaking treatments for many childhood cancers, studies to better understand these diseases, and trials focused around supportive care and survivorship.

Renown is now enrolling pediatric patients in clinical trials through the COG. Through this process, many childhood cancer patients will be eligible to receive newly-developed therapies.  For example, some trials employ immunotherapeutic drugs in addition to conventional chemotherapy, in hopes that adding the immunotherapy results in better health outcomes for pediatric cancer patients.

"As a pediatric intensivist by training, I understand how quickly advancements are made in pediatric medicine," said Tony Slonim, MD, DrPH, President & CEO of Renown Health. "As a member of the COG, pediatric oncology patients of Renown Children's Hospital now have access to the latest and most cutting-edge treatment options in addition to commonly prescribed treatments. I am proud of the highly-skilled caregivers at Renown who are constantly expanding their knowledge and contributing research to give our pediatric patients and their families hope for the future."

"Until now, we have been able to offer treatments at Renown based on the current standard of care, which means the treatment is based on published trial results that may not reflect the latest research in the field," said Renown's Chief of Hematology/Oncology, J. Martin Johnston, MD. "Previously, a pediatric oncology patient could only enroll in a COG trial if the family had the capacity to temporarily relocate to the Bay Area or Salt Lake City, for example. Now, our patients will have the opportunity to enroll in these trials without the need to travel so far from home."

"When faced with pediatric cancer, the last thing parents should worry about is traveling great lengths to receive the best in cancer care," said Larry Duncan, Vice President of Pediatrics and Surgery and Administrator, Renown Children's. "We are proud to now offer the most advanced childhood cancer treatment options here at Renown, close to home and convenient for area patients and their families. We always strive to see more patients beat cancer, and being part of the COG helps our expert team of pediatric oncologists implement innovative and new ways to make that happen."

Austin, el hijo de Brenda Milligan, residente de Carson City, tenía 5 años cuando le diagnosticaron leucemia y recibió tratamiento en el Renown Children’s Hospital. As an active participant in her now 10-year-old son's treatment plan, Brenda shares that she regularly sought out advice from COG providers across the country and is pleased that northern Nevadan parents of children being treated for leukemia can now take full advantage of the COG right at home.

"The COG allows Renown's providers to have access to treatment plans that weren't available when Austin was receiving treatment," said Brenda. "It comforts me to know that not only can children receive cancer treatment right at home, but their parents can now elect for them to participate in trials and plans that are at the forefront of cancer treatment today."

According to the COG, more than 90 percent of 14,000 U.S. children and adolescents diagnosed with cancer annually are cared for at COG member institutions. Como institución miembro del COG, Renown se une a más de 200 instituciones, entre ellas Stanford, UCSF y Kaiser Permanente, en este prestigioso honor. El COG está compuesto por más de 9,000 expertos en todo el mundo y tiene alrededor 100 de estudios clínicos traslacionales activos que se llevan a cabo de manera simultánea.

Research from the COG has drastically transformed children's cancer outcomes. Hace solo 50 años, se pensaba que el cáncer pediátrico era intratable; mientras que hoy, tiene una tasa de supervivencia combinada a cinco años del 80 %.

"The key to ending childhood cancer is through extensive scientific research and clinical trials," said Max Coppes, Cancer Center Director at Renown Institute for Cancer. "As a COG member institution, our doctors will have the opportunity to collaborate with other pediatric oncologists around the world who share a common goal—to cure all children of cancer. At Renown, we are proud to be at the forefront of life-saving research and treatments for pediatric oncology patients throughout our region."

“También agradecemos a William N. Pennington Foundation por su apoyo para establecer el Fondo William N. Pennington para la atención pediátrica avanzada en 2016, que nos permitió contratar a más de 15 pediatras especializados, incluso en oncología/hematología, lo cual fue crucial para nuestra solicitud para la membresía del COG”.




About Renown Children's Hospital

Renown Children's Hospital is the only dedicated children's hospital in northern Nevada, and offers a variety of programs and services designed specifically to care for families in our community. It has the region's only pediatric ER and ICU. Renown Children's Hospital is not-for-profit and relies on philanthropic support. Visit renown.org/give to support Renown Children's Hospital. For more information on programs and services, visit renown.org/children.

Media Contact

Renown Public Relations

¡Escríbanos! news@renown.org


Noticias relacionadas

Ver todos los comunicados de prensa